Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

The user noticed a slight loss of progress after switching to Milpharm finasteride 1mg and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.

The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. Users share experiences and results with these treatments.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

The user experienced significant hair regrowth in the temple area after using 1mg finasteride daily for over a year, with no side effects. The user did not use minoxidil or microneedling and started experiencing hair loss at age 16.

The user is using Minoxidil, Finasteride, microneedling, and plans to add low-level laser therapy (LLLT) to treat hair thinning. They shared progress pictures showing results from May 8th to June 7th.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.

The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.

A user shared their positive experience with a 2987 graft hair transplant focused on the hairline, supplemented by finasteride and minoxidil for the mid scalp and crown. They expressed satisfaction with the results and the supportive care received during and after the procedure.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

A 20-year-old male has been using a topical mix of finasteride, minoxidil, and tretinoin for five months without seeing significant hairline improvement. He is considering adding oral dutasteride or a hair transplant for better results.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

A 45-year-old male successfully slowed hair loss using Nizoral and low-level laser therapy (LLLT) but cannot use Minoxidil, finasteride, or dutasteride for medical reasons. He seeks suggestions for hair regrowth options.

The user has been using a topical solution of minoxidil 5% and finasteride 0.025% daily, along with dermastamping every two weeks and ketoconazole shampoo twice a week for four months. The treatment is for hair loss.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.